[Tanakan in the treatment of perinatal injuries of the central nervous system].
Clinical laboratory investigation of the efficiency of Tanakan (Beaufour Ipsen, France) was performed in 30 children (20 girls, 10 boys) of 2-7 months old with hypoxic-ischemic encephalopathy. Tanakan was taken per os 2 times a day (in the morning and dinner time) as a 0.25 ml of standard solution for 2 months. Other vasoactive, nootropic and antiaggregative drugs weren't used. Clinical-neurologic, neurosonographic studies, ultrasonic dopplerography of intracranial arteries were performed before and after the course of treatment. Efficiency of Tanakan was established in hypoxic-ischemic encephalopathy in children of an early age. By increasing a cerebral blood flow and decreasing intracranial pressure, the drug had positive influence on the motor functions and psychoemotional sphere, promoting a considerable decrease of vegetovisceral and vegetovascular disorders. Side-effects of Tanakan administration were not observed.
Shprakh
V V
VV
Saiutina
S B
SB
Revezova
T V
TV
Pak
K O
KO
Arbatskaia
O Iu
OIu
D002491:Central Nervous System Agents / Q000627:therapeutic use*; D005260:Female; D005419:Flavonoids / Q000627:therapeutic use*; D020441:Ginkgo biloba; D006801:Humans; D020925:Hypoxia-Ischemia, Brain / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000209:etiology; D007223:Infant; D008297:Male; D010936:Plant Extracts; D013345:Subarachnoid Hemorrhage / Q000150:complications*; D016896:Treatment Outcome; D014463:Ultrasonography; D000096983:Ginkgo Extract
D002491:Central Nervous System Agents; D005419:Flavonoids; D010936:Plant Extracts; C063170:Ginkgo biloba extract; D000096983:Ginkgo Extract